Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer

Giuseppe Curigliano, Xavier Pivot, Javer Cortés, Anthony Elias, Rossano Cesari, Reza Khosravan, Mary Collier, Xin Huang, Patricia E. Cataruozolo, Kenneth A. Kern, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

Purpose: This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC). Methods: Patients with advanced TNBC, relapsed after anthracycline- and taxane-based chemotherapy, were randomized to receive either sunitinib (37.5mg/day) or the investigator's choice of SOC therapy. Progression-free survival was the primary endpoint. Results: Median progression-free survival was 2.0 months with sunitinib and 2.7 months with SOC chemotherapy (one-sided P=0.888). Median overall survival was not prolonged with sunitinib (9.4 months) compared with SOC chemotherapy (10.5 months; one-sided P=0.839). The objective response rate was 3% with sunitinib and 7% with SOC chemotherapy (one-sided P=0.962). Conclusions: Sunitinib monotherapy did not improve efficacy compared with SOC chemotherapy in patients with previously treated advanced TNBC, for which identification of effective treatments and therapeutic targets remains an urgent need. Trial registration: NCT00246571.

Original languageEnglish
Pages (from-to)650-656
Number of pages7
JournalBreast
Volume22
Issue number5
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Standard of Care
Triple Negative Breast Neoplasms
Drug Therapy
Disease-Free Survival
Anthracyclines
sunitinib
Therapeutics
Research Personnel
Survival

Keywords

  • Phase II
  • Receptor tyrosine kinases
  • Standard-of-care chemotherapy
  • Sunitinib
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer. / Curigliano, Giuseppe; Pivot, Xavier; Cortés, Javer; Elias, Anthony; Cesari, Rossano; Khosravan, Reza; Collier, Mary; Huang, Xin; Cataruozolo, Patricia E.; Kern, Kenneth A.; Goldhirsch, Aron.

In: Breast, Vol. 22, No. 5, 10.2013, p. 650-656.

Research output: Contribution to journalArticle

Curigliano, G, Pivot, X, Cortés, J, Elias, A, Cesari, R, Khosravan, R, Collier, M, Huang, X, Cataruozolo, PE, Kern, KA & Goldhirsch, A 2013, 'Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer', Breast, vol. 22, no. 5, pp. 650-656. https://doi.org/10.1016/j.breast.2013.07.037
Curigliano, Giuseppe ; Pivot, Xavier ; Cortés, Javer ; Elias, Anthony ; Cesari, Rossano ; Khosravan, Reza ; Collier, Mary ; Huang, Xin ; Cataruozolo, Patricia E. ; Kern, Kenneth A. ; Goldhirsch, Aron. / Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer. In: Breast. 2013 ; Vol. 22, No. 5. pp. 650-656.
@article{3792a88294314583b282a500f2afc9d2,
title = "Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer",
abstract = "Purpose: This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC). Methods: Patients with advanced TNBC, relapsed after anthracycline- and taxane-based chemotherapy, were randomized to receive either sunitinib (37.5mg/day) or the investigator's choice of SOC therapy. Progression-free survival was the primary endpoint. Results: Median progression-free survival was 2.0 months with sunitinib and 2.7 months with SOC chemotherapy (one-sided P=0.888). Median overall survival was not prolonged with sunitinib (9.4 months) compared with SOC chemotherapy (10.5 months; one-sided P=0.839). The objective response rate was 3{\%} with sunitinib and 7{\%} with SOC chemotherapy (one-sided P=0.962). Conclusions: Sunitinib monotherapy did not improve efficacy compared with SOC chemotherapy in patients with previously treated advanced TNBC, for which identification of effective treatments and therapeutic targets remains an urgent need. Trial registration: NCT00246571.",
keywords = "Phase II, Receptor tyrosine kinases, Standard-of-care chemotherapy, Sunitinib, Triple-negative breast cancer",
author = "Giuseppe Curigliano and Xavier Pivot and Javer Cort{\'e}s and Anthony Elias and Rossano Cesari and Reza Khosravan and Mary Collier and Xin Huang and Cataruozolo, {Patricia E.} and Kern, {Kenneth A.} and Aron Goldhirsch",
year = "2013",
month = "10",
doi = "10.1016/j.breast.2013.07.037",
language = "English",
volume = "22",
pages = "650--656",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer

AU - Curigliano, Giuseppe

AU - Pivot, Xavier

AU - Cortés, Javer

AU - Elias, Anthony

AU - Cesari, Rossano

AU - Khosravan, Reza

AU - Collier, Mary

AU - Huang, Xin

AU - Cataruozolo, Patricia E.

AU - Kern, Kenneth A.

AU - Goldhirsch, Aron

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC). Methods: Patients with advanced TNBC, relapsed after anthracycline- and taxane-based chemotherapy, were randomized to receive either sunitinib (37.5mg/day) or the investigator's choice of SOC therapy. Progression-free survival was the primary endpoint. Results: Median progression-free survival was 2.0 months with sunitinib and 2.7 months with SOC chemotherapy (one-sided P=0.888). Median overall survival was not prolonged with sunitinib (9.4 months) compared with SOC chemotherapy (10.5 months; one-sided P=0.839). The objective response rate was 3% with sunitinib and 7% with SOC chemotherapy (one-sided P=0.962). Conclusions: Sunitinib monotherapy did not improve efficacy compared with SOC chemotherapy in patients with previously treated advanced TNBC, for which identification of effective treatments and therapeutic targets remains an urgent need. Trial registration: NCT00246571.

AB - Purpose: This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC). Methods: Patients with advanced TNBC, relapsed after anthracycline- and taxane-based chemotherapy, were randomized to receive either sunitinib (37.5mg/day) or the investigator's choice of SOC therapy. Progression-free survival was the primary endpoint. Results: Median progression-free survival was 2.0 months with sunitinib and 2.7 months with SOC chemotherapy (one-sided P=0.888). Median overall survival was not prolonged with sunitinib (9.4 months) compared with SOC chemotherapy (10.5 months; one-sided P=0.839). The objective response rate was 3% with sunitinib and 7% with SOC chemotherapy (one-sided P=0.962). Conclusions: Sunitinib monotherapy did not improve efficacy compared with SOC chemotherapy in patients with previously treated advanced TNBC, for which identification of effective treatments and therapeutic targets remains an urgent need. Trial registration: NCT00246571.

KW - Phase II

KW - Receptor tyrosine kinases

KW - Standard-of-care chemotherapy

KW - Sunitinib

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84884151634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884151634&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.07.037

DO - 10.1016/j.breast.2013.07.037

M3 - Article

C2 - 23958375

AN - SCOPUS:84884151634

VL - 22

SP - 650

EP - 656

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -